论文部分内容阅读
本文通过对４８例冠心病（ＣＨＤ）患者外周血循环内皮细胞（ＣＥＣ）、内皮素（ＥＴ）、血管紧张素转换酶（ＡＣＥ）和前列环素（ＰＧＩ２）代谢产物６－酮类固醇－前列腺素Ｆ１ａ（６－ｋｅｔｏ－ＰＧＦ１ａ）的测定，以了解ＣＨＤ患者血管内皮细胞（ＶＥＣ）的损伤情况及功能变化，并与正常人及卡托普利（Ｃａｐ）治疗前后进行对比。结果显示：ＣＨＤ患者血浆ＣＥＣ、ＥＴ、ＡＣＥ明显高于正常；６－ｋｅｔｏ－ＰＧＦ１ａ则明显低于正常，且与病情严重程度相一致。ＣＥＣ与ＥＴ、ＡＣＥ呈显著正相关；与６－ｋｅｔｏ－ＰＧＦ１ａ呈显著负相关。通过Ｃａｐ治疗后上述指标明显改善，治疗前后及与对照组比较有非常显著意义（Ｐ＜０．０１），提示Ｃａｐ对ＣＨＤ患者的ＶＥＣ损伤有较好的保护和治疗作用。
In this paper, 48 patients with coronary heart disease (CHD) in patients with peripheral blood circulating endothelial cells (CEC), endothelin (ET), angiotensin converting enzyme (ACE) and PGI2 metabolites 6-ketosteroid - prostaglandin F1a (6-keto-PGF1a) in order to understand the damage and function changes of vascular endothelial cells (VEC) in patients with CHD and to compare them with those before and after treatment with Cap and normal people. The results showed that the plasma levels of CEC, ET and ACE in CHD patients were significantly higher than those in normal controls. The levels of 6-keto-PGF1a in patients with CHD were significantly lower than those in normal controls and were consistent with the severity of the disease. There was a significant positive correlation between CEC and ET and ACE, but negatively correlated with 6-keto-PGF1a. The above indexes were significantly improved after treatment with Cap, with significant difference before and after treatment and compared with the control group (P <0.01), suggesting that Cap has a good protective and therapeutic effect on VEC injury in CHD patients.